The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo

Leukemia Research

Volumn 35, Issue 3, 2011, Pages 373-379

  Sanchez, Eric ^a   Shen, Jing ^a   Steinberg, Jeffrey ^a   Li, Mingjie ^a   Wang, Cathy ^a   Bonavida, Benjamin ^b   Chen, Haiming ^a   Li, Zhi Wei ^a   Berenson, James R ^a  

^a INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; Histone deacetylase inhibitor; In vivo; LBH589; Multiple myeloma

Indexed keywords

CASPASE; DOXORUBICIN; MELPHALAN; PANOBINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; TUMOR XENOGRAFT;

ACETYLATION; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG SYNERGISM; FLOW CYTOMETRY; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; IMMUNOGLOBULIN G; MELPHALAN; MICE; MICE, SCID; MULTIPLE MYELOMA;

EID: 79952108058     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.06.026     Document Type: Article

References (38)

1. Bergsagel P.L., Kuehl W.M. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005, 23:6333-6338.
2. Stewart A.K., Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 2005, 23:6339-6344.
3. Wade P.A. Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet 2001, 10:693-698.
4. Cress W.D., Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000, 184:1-16.
5. Mahlknecht U., Hoelzer D. Histone acetylation modifiers in the pathogenesis of malignant disease. Mol Med 2000, 6:623-644.
6. Carew J.S., Giles F.J., Nawrocki S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008, 269:7-17.
7. Feng R., Oton A., Mapara M.Y., Anderson G., Belani C., Lentzsch S. The histone deacetylase inhibitor. PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol 2007, 139:385-397.
8. Khan S.B., Maududi T., Barton K., Ayers J., Alkan S. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol 2004, 125:156-161.
9. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Shringarpure R., Hideshima T., et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 2004, 101:540-545.
10. Spanswick V.J., Craddock C., Sekhar M., Mahendra P., Shankaranarayana P., Hughes R.G., et al. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 2002, 100:224-229.
11. Alexanian R., Bergsagel D.E., Migliore P.J., Vaughn W.K., Howe C.D. Melphalan therapy for plasma cell myeloma. Blood 1968, 31:1-10.
12. Waterhouse D.N., Tardi P.G., Mayer L.D., Bally M.B. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Safety 2001, 24:903-920.
13. Ma M.H., Yang H.H., Parker K., Manyak S., Friedman J.M., Altamirano C., et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003, 9:1136-1144.
14. Berenson J.R., Yang H.H., Sadler K., Jarutirasarn S.G., Vescio R.A., Mapes R., et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006, 24:937-944.
15. Berenson J.R., Yellin O., Woytowitz D., Flam M.S., Cartmell A., Patel R., Duvivier H., et al. Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen. Blood 2007, 110. Abstract 3602.
16. Orlowski R.Z., Nagler A., Sonneveld P., Blade J., Hajek R., Spencer A., et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007, 25:3892-3901.
17. San Miguel J.F., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., Kropff M., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359:906-917.
18. Hideshima T., Chauhan D., Shima Y., Raje N., Davies F.E., Tai Y.T., et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96:2943-2950.
19. Facon T., Mary J.Y., Hulin C., Benboubker L., Attal M., Pegourie B., et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007, 370:1209-1218.
20. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 2009, 280:233-241.
21. Bluethner T., Niederhagen M., Caca K., Serr F., Witzigmann H., Moebius C., et al. Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach. World J Gastroenterol 2007, 13:4761-4770.
22. Qian D.Z., Kato Y., Shabbeer S., Wei Y., Verheul H.M., Salumbides B., et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 2006, 12:634-642.
23. Edwards A., Li J., Atadja P., Bhalla K., Haura E.B. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther 2007, 6:2515-2524.
24. Yu C., Friday B.B., Lai J.P., McCollum A., Atadja P., Roberts L.R., et al. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. Clin Cancer Res 2007, 13:1140-1148.
25. Crisanti M.C., Wallace A.F., Kapoor V., Vandermeers F., Dowling M.L., Pereira L.P., et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther 2009, 8:2221-2231.
26. Floris G., Debiec-Rychter M., Sciot R., Stefan C., Fieuws S., Machiels K., et al. High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model. Clin Cancer Res 2009, 15:4066-4076.
27. Catley L., Weisberg E., Kiziltepe T., Tai Y.T., Hideshima T., Neri P., et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006, 108:3441-3449.
28. Maiso P., Carvajal-Vergara X., Ocio E.M., Lopez-Perez R., Mateo G., Gutierrez N., et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006, 66:5781-5789.
29. Ocio E.M., Vilanova D., Atadja P., Maiso P., Crusoe E., Fernandez-Lazaro D., et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica 2009, Epub ahead of print.
30. Campbell R.A., Manyak S.J., Yang H.H., Sjak-Shie N.N., Chen H., Gui D., et al. LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma. Int J Oncol 2006, 28:1409-1417.
31. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
32. Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 2006, 94:179-183.
33. Higashitsuji H., Masuda T., Liu Y., Itoh K., Fujita J. Enhanced deacetylation of p53 by the anti-apoptotic protein HSCO in association with histone deacetylase 1. J Biol Chem 2007, 282:13716-13725.
34. Zhao Y., Tan J., Zhuang L., Jiang X., Liu E.T., Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA 2005, 102:16090-16095.
35. Mazars G.R., Portier M., Zhang X.G., Jourdan M., Bataille R., Theillet C., et al. Mutations of the p53 gene in human myeloma cell lines. Oncogene 1992, 7:1015-1018.
36. Mitsiades N., Mitsiades C.S., Richardson P.G., McMullan C., Poulaki V., Fanourakis G., et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003, 101:4055-4062.
37. Ruefli A.A., Ausserlechner M.J., Bernhard D., Sutton V.R., Tainton K.M., Kofler R., et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001, 98:10833-10838.
38. Berenson J.R., Yellin O., Boccia R.V., Nassir Y., Rothstein S., Swift R.A. A phase I study of oral melphalan combined with LBH589 for patients with relapsed or refractory multiple myeloma (MM). Blood 2009, 114. Abstract 1855.